Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 10, 2020 / 05:35PM GMT
Release Date Price: €16.6 (-13.09%)
Operator

Mr. Prasad, you may begin.

Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Thank you. Good afternoon, everyone. Thank you for dialing in. My name is Balaji Prasad. I lead spec pharma coverage for Barclays. This is a continuation of our virtual health care conference. And continuing with the day, we have with us today for the session with Revance, Mark Foley, CEO; and Jeanie from Investor Relations.

Also, owing to the nature of this format, there will be no Q&A session.

Mark and Jeanie, welcome, and thanks for taking your time.

Mark J. Foley
Revance Therapeutics, Inc. - President, CEO & Director

Thanks, Balaji. Thanks for having us.

Questions & Answers

Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Yes, pleasure. Mark, it's been 5 months now since you took over as CEO. We had the pleasure of hosting you on your first roadshow a few months ago, and now it's great to have you here. Before I even

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot